title: Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.
abstract: Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb in vitro or in vivo.
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Jianxuan
authors: J
authors: Zou
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Dan
authors: D
authors: Chen
authors: Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China.
authors: Yunhui
authors: Y
authors: Zong
authors: Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China.
authors: Sisi
authors: S
authors: Ye
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Jinle
authors: J
authors: Tang
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Huimin
authors: H
authors: Meng
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Gangli
authors: G
authors: An
authors: Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China.
authors: Xingding
authors: X
authors: Zhang
authors: The Cyrus Tang Hematology Center, Soochow University, Suzhou, China.|Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
authors: Lin
authors: L
authors: Yang
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D018033:Antibodies, Bispecific / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015703:Antigens, CD / Q000378:metabolism; D000945:Antigens, Differentiation, T-Lymphocyte / Q000378:metabolism; D017252:CD3 Complex / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D045744:Cell Line, Tumor; D006801:Humans; D007074:Immunoglobulin G / Q000235:genetics / Q000276:immunology; D007167:Immunotherapy / Q000379:methods*; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology / Q000378:metabolism; D037181:Lectins, C-Type / Q000378:metabolism; D016513:Mice, SCID; D008969:Molecular Sequence Data; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D017452:Receptors, IgG / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D057127:Single-Chain Antibodies / Q000235:genetics / Q000276:immunology*; D053668:Syndecan-1 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D023041:Xenograft Model Antitumor Assays; D000099192:CD69 Antigens
chemical_list: D018033:Antibodies, Bispecific; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D007074:Immunoglobulin G; D053645:Interleukin-2 Receptor alpha Subunit; D037181:Lectins, C-Type; D017452:Receptors, IgG; D011994:Recombinant Proteins; D057127:Single-Chain Antibodies; D053668:Syndecan-1; D000099192:CD69 Antigens; C508017:IL2RA protein, human; C508241:SDC1 protein, human
keywords: Bispecific antibodies; T cells; immunotherapy; multiple myeloma; natural killer cells